Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Debt to Equity (2018 - 2026)

Akebia Therapeutics has reported Debt to Equity over the past 8 years, most recently at $1.48 for Q4 2025.

  • Quarterly Debt to Equity rose 288.08% to $1.48 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.48 through Dec 2025, up 288.08% year-over-year, with the annual reading at $1.48 for FY2025, 288.08% up from the prior year.
  • Debt to Equity was $1.48 for Q4 2025 at Akebia Therapeutics, up from $1.15 in the prior quarter.
  • Over five years, Debt to Equity peaked at $12.63 in Q4 2022 and troughed at -$2.63 in Q1 2023.
  • The 5-year median for Debt to Equity is $0.63 (2021), against an average of $1.28.
  • Year-over-year, Debt to Equity soared 1026.32% in 2022 and then tumbled 195.17% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $1.32 in 2021, then soared by 858.6% to $12.63 in 2022, then tumbled by 108.98% to -$1.13 in 2023, then surged by 30.63% to -$0.79 in 2024, then skyrocketed by 288.08% to $1.48 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Debt to Equity are $1.48 (Q4 2025), $1.15 (Q3 2025), and $1.61 (Q2 2025).